Department of Epidemiology, Infectious Disease Control and Prevention, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.
Health Service Center, Hiroshima University, Hiroshima, Japan.
Vaccine. 2019 Jan 3;37(1):145-151. doi: 10.1016/j.vaccine.2018.11.019. Epub 2018 Nov 16.
Health care workers (HCWs) are at high risk of contracting blood-borne infections including hepatitis B virus (HBV) infection. In Japan, all HCWs are required to receive HB vaccination before beginning work. This study aimed to investigate the dynamics of the HB surface antibody (anti-HBs) titer after a three-dose HB vaccination in HCWs and to determine effective scheduling of HB vaccination for non-responders.
Subjects included 832 medical and dental students who had received a three-dose HB vaccination (Bimmugen® 0.5 ml/vial). Anti-HBs was measured three times (before the third dose and 1 and 5 months after the third dose) using the CLIA method. The cut-off value of anti-HBs acquisition was 10 mIU/mL. After booster doses (three maximum) were administered to non-responders, the anti-HBs titers were measured again.
Out of 832 students, 491 were analyzed, of which 58.9% (289) were male. Anti-HBs-positive rates before the third dose and 1 and 5 months later were 47.9%, 95.9%, and 89.0%, respectively. The relationship between the antibody titer at one month (x) and 5 months (y) was estimated by logy = logx - 0.134 (P < 0.0001). Twelve non-responders were followed-up, all of which acquired a protective anti-HBs titer after revaccination with a three-dose booster.
Anti-HBs titer decreases by an average of 20% within 4 months between the 1st and 5th month after the third dose. Therefore, anti-HBs titer should be measured periodically after completing the three-dose vaccination. Additionally, results suggested that booster doses are effective if administered with the same schedule as primary vaccination.
医护人员(HCWs)感染血源性病原体的风险较高,包括乙型肝炎病毒(HBV)感染。在日本,所有 HCWs 在开始工作前都必须接种乙型肝炎疫苗。本研究旨在调查三剂乙型肝炎疫苗接种后 HCWs 乙型肝炎表面抗体(抗-HBs)滴度的动态变化,并确定对无应答者进行乙型肝炎疫苗接种的有效方案。
本研究纳入了 832 名接受三剂乙型肝炎疫苗(Bimmugen® 0.5ml/剂)接种的医学生和牙科学生。使用 CLIA 法在三次(第三剂前、第三剂后 1 个月和 5 个月)检测抗-HBs。抗-HBs 获得的临界值为 10mIU/ml。对无应答者进行三次(最多三次)加强剂量后,再次测量抗-HBs 滴度。
在 832 名学生中,对 491 名学生进行了分析,其中 58.9%(289 名)为男性。第三剂前、第三剂后 1 个月和 5 个月的抗-HBs 阳性率分别为 47.9%、95.9%和 89.0%。通过对数 y=logx-0.134(P<0.0001)来估计一个月(x)和五个月(y)之间的抗体滴度关系。对 12 名无应答者进行了随访,所有无应答者在接受三剂加强剂量疫苗接种后均获得了保护性抗-HBs 滴度。
第三剂后 1 至 5 个月内,抗-HBs 滴度平均下降 20%。因此,三剂疫苗接种完成后应定期测量抗-HBs 滴度。此外,如果按照与初次接种相同的方案进行加强剂量接种,则结果表明加强剂量是有效的。